Celgene (CELG) Down On Talk of REVLIMID Warning
More News related to CELG
- Celgene Corporation to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
- US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients During Early Morning Period
- 128 Abstracts Evaluating Celgene Products to Be Presented at the 50th Annual American Society of Hematology Meeting
- Celgene (CELG) Subsidiary Announces FDA Accepts NDA on PDA001
- Celgene Cellular Therapeutics Receives FDA Clearance for First Placenta-Derived Stem Cell Clinical Study
More News related to Rumors
- Sources Say 'Highly Unlikely' That Miller Buys Yahoo! (YHOO) -CNBC
- Reports Former AOL CEO Raising Money For Yahoo! (YHOO) Deal
- Former AOL CEO John Miller In Talks With PE Shops To Buy Yahoo (YHOO)
- Reports Total Is Preparing A Bid For NEXEN (NXY)
- NEXEN (NXY) Pops On Buyout Talk
Celgene Corporation (Nasdaq: CELG) is seeing some weakness over the past 30 minutes on word of some type of FDA warning on REVLIMID.
Related Categories
FDARumors
Stocks Mentioned
+3.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
